Clark Hill Member Gerald Schneeweis Published in DRI’s Drug and Medical Device Committee Rx for the Defense
Member Gerald Schneeweis’s article “On the Banks of the Stream of Commerce: Why There Should Be No Individual ‘Product’ Liability of Corporate Officers, Directors and Employees” was published today in the Defense Research Institute (DRI) Drug and Medical Device Committee’s Newsletter Rx for the Defense. In this article, Schneeweis describes the trend of plaintiffs to bring “product” liability claims against not only the company as an enterprise but also against corporate individuals and defends why some individuals should not be subject to individual “product” liability. To view the article, click here.
Schneeweis is a Member in Clark Hill’s Litigation practice group. He has represented pharmaceutical and medical device manufacturers, research entities and individual officers, directors and employees in product liability litigation asserting claims of design and manufacturing defect, failure to warn and off-label promotion. Schneeweis is a member of the DRI Drug & Medical Device Committee, the San Diego chapter of the American Board of Trial Advocates and the American Bar Association.
What's Hot in the U.S. Crime Market - Part III
Please join us for a fast-moving presentation on the important current trends in the crime and related insurance coverage markets.
Post-Merger Integration Challenges in the Cannabis Industry
Join us for a thoughtful discussion which will cover M&A project integration plan outlines. We will discuss the timeline for major resources, assets, and processes of the acquiring and acquired companies that will be combined in order to achieve the goals of the deal.
Addressing the Ramifications of Federal Legalization for the U.S. Cannabis Industry
The cannabis industry rang in 2021 with high hopes of federal legalization, leading to a massive run-up in cannabis equity values. Eighteen months later, however, proposals for federal legalization continue to stagnate and the industry remains beset with the unfair tax burdens, transactions costs and regulatory nightmares created by prohibition. Many wonder, what is taking Congress so long to pass a bill de-scheduling cannabis?